1Associate Professor, Department of Pharmaceutics, Malla Reddy College of Pharmacy, Maisammaguda, Hyderabad, Telangana-500014
2Professor, Department of Pharmaceutical Technology, Netaji Institute of Pharmaceutical Sciences, Toopranpet, Yadadri Bhongir, Telangana-508252
3Associate Professor, Department of Pharmaceutical Analysis and Quality Assurance, MNR college of Pharmacy Fasalwadi, Sangareddy, Medak, Telangana, 502294, India
4Associate Professor, Department of Pharmaceutics, Anwar-ul-Uloom College of Pharmacy, Rangareddy, Telangana, India
5Associate Professor, Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy College of Pharmacy, Maisammaguda, Hyderabad, Telangana-500014
*Corresponding Author E-mail: Sahoo.chinmaya83@gmail.com
Online published on 29 April, 2017.
The objective of the present study was to develop an immediate release tablet of Dasatinib using different concentrations of cross carmelose sodium (CCS) as superdisintegrant with a view to gain rapid disintegration in gastric pH for treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Five different formulations of Dasatinib immediate release tablets were prepared using wet granulation method. Different pre compression and post compression characterization of tablet was carried out. In vitro drug release studies were carried out in USP II paddle type dissolution apparatus for different formulation and the batch containing 5% CCS gave maximum amount of drug release of 99.14%. Drug and excipients compatibility studies were carried out through FTIR spectroscopy. FTIR spectroscopy studies reveled that there is no interaction between drug and different excipients used in formulation. Short term stability studies (at 40±2ºC/75±5% RH) on the best formulation indicated that there no significant changes in drug content.
Immediate release tablets, Dasatinib, CCS, in vitro drug release study, FTIR spectroscopy
